Is Syndax Pharmaceuticals Stock a Good Investment?
Syndax Pharmaceuticals Investment Advice | SNDX |
- Examine Syndax Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Syndax Pharmaceuticals' leadership team and their track record. Good management can help Syndax Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Syndax Pharmaceuticals' business and its evolving consumer preferences.
- Compare Syndax Pharmaceuticals' performance and market position to its competitors. Analyze how Syndax Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Syndax Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Syndax Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Syndax Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Syndax Pharmaceuticals is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Syndax Pharmaceuticals Stock
Researching Syndax Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are owned by institutional investors. The book value of Syndax Pharmaceuticals was at this time reported as 4.28. The company has Price/Earnings (P/E) ratio of 126.11. Syndax Pharmaceuticals recorded a loss per share of 3.64. The entity had not issued any dividends in recent years.
To determine if Syndax Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Syndax Pharmaceuticals' research are outlined below:
| Syndax Pharmaceuticals generated a negative expected return over the last 90 days | |
| Syndax Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (209.36 M) with profit before overhead, payroll, taxes, and interest of 139.71 M. | |
| Syndax Pharmaceuticals currently holds about 350.71 M in cash with (160.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.82. | |
| Syndax Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Syndax Pharmaceuticals Stock Price Expected to Rise, Citigroup Analyst Says |
Syndax Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Syndax Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Syndax Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Syndax Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Syndax Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-03-08 | 2020-12-31 | -0.49 | -0.44 | 0.05 | 10 | ||
2019-11-07 | 2019-09-30 | -0.47 | -0.41 | 0.06 | 12 | ||
2016-08-09 | 2016-06-30 | -0.53 | -0.47 | 0.06 | 11 | ||
2018-11-05 | 2018-09-30 | -0.76 | -0.68 | 0.08 | 10 | ||
2016-11-10 | 2016-09-30 | -0.76 | -0.84 | -0.08 | 10 | ||
2023-08-03 | 2023-06-30 | -0.73 | -0.64 | 0.09 | 12 | ||
2024-08-01 | 2024-06-30 | -0.91 | -0.8 | 0.11 | 12 | ||
2021-05-11 | 2021-03-31 | -0.65 | -0.54 | 0.11 | 16 |
Know Syndax Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Syndax Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Syndax Pharmaceuticals backward and forwards among themselves. Syndax Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Syndax Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Orbimed Advisors, Llc | 2024-06-30 | 1.9 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 1.8 M | Franklin Resources Inc | 2024-09-30 | 1.8 M | Stempoint Capital Lp | 2024-09-30 | 1.7 M | Woodline Partners Lp | 2024-06-30 | 1.5 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.5 M | Goldman Sachs Group Inc | 2024-06-30 | 1.4 M | First Turn Management Llc | 2024-09-30 | 1.2 M | Millennium Management Llc | 2024-06-30 | 1.1 M | Blackrock Inc | 2024-06-30 | 7.9 M | Wellington Management Company Llp | 2024-06-30 | 7.3 M |
Syndax Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.43 B.Market Cap |
|
Syndax Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.41) | (0.44) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (0.38) | (0.40) |
Determining Syndax Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Syndax Pharmaceuticals is a good buy. For example, gross profit margin measures Syndax Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Syndax Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Syndax Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Syndax Pharmaceuticals. Check Syndax Pharmaceuticals' Beneish M Score to see the likelihood of Syndax Pharmaceuticals' management manipulating its earnings.
Evaluate Syndax Pharmaceuticals' management efficiency
Syndax Pharmaceuticals has return on total asset (ROA) of (0.4867) % which means that it has lost $0.4867 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8188) %, meaning that it created substantial loss on money invested by shareholders. Syndax Pharmaceuticals' management efficiency ratios could be used to measure how well Syndax Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.36 in 2024. Return On Capital Employed is likely to drop to -0.44 in 2024. At this time, Syndax Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 33.6 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 646 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.88 | 8.27 | |
| Tangible Book Value Per Share | 7.88 | 8.27 | |
| Enterprise Value Over EBITDA | (5.34) | (5.60) | |
| Price Book Value Ratio | 2.74 | 2.88 | |
| Enterprise Value Multiple | (5.34) | (5.60) | |
| Price Fair Value | 2.74 | 2.88 | |
| Enterprise Value | 1.2 B | 1.3 B |
Management at Syndax Pharmaceuticals focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Beta 0.917 |
Basic technical analysis of Syndax Stock
As of the 26th of November, Syndax Pharmaceuticals has the Variance of 16.77, risk adjusted performance of (0.03), and Coefficient Of Variation of (1,854). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Syndax Pharmaceuticals, as well as the relationship between them.Syndax Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Syndax Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Syndax Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Syndax Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gallagher Neil over two months ago Acquisition by Gallagher Neil of 69375 shares of Syndax Pharmaceuticals at 22.28 subject to Rule 16b-3 | ||
Jarrett Jennifer over three months ago Acquisition by Jarrett Jennifer of 17000 shares of Syndax Pharmaceuticals subject to Rule 16b-3 | ||
Peter Ordentlich over six months ago Acquisition by Peter Ordentlich of 90000 shares of Syndax Pharmaceuticals at 28.55 subject to Rule 16b-3 | ||
Briggs Morrison over six months ago Acquisition by Briggs Morrison of 52855 shares of Syndax Pharmaceuticals at 8.77 subject to Rule 16b-3 | ||
Dennis Podlesak over six months ago Acquisition by Dennis Podlesak of 34000 shares of Syndax Pharmaceuticals subject to Rule 16b-3 | ||
Peter Ordentlich over a year ago Exercise or conversion by Peter Ordentlich of 7572 shares of Syndax Pharmaceuticals subject to Rule 16b-3 |
Syndax Pharmaceuticals' Outstanding Corporate Bonds
Syndax Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Syndax Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Syndax bonds can be classified according to their maturity, which is the date when Syndax Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| SNV 5625 15 FEB 28 Corp BondUS87164DVJ61 | View | |
| SYNCHRONY FINL 45 Corp BondUS87165BAG86 | View | |
| SYNCHRONY FINL 395 Corp BondUS87165BAM54 | View | |
| SYNCHRONY FINL 37 Corp BondUS87165BAL71 | View | |
| SYF 4875 13 JUN 25 Corp BondUS87165BAS25 | View | |
| SYF 2875 28 OCT 31 Corp BondUS87165BAR42 | View |
Understand Syndax Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Syndax Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.08) | |||
| Mean Deviation | 2.32 | |||
| Coefficient Of Variation | (1,854) | |||
| Standard Deviation | 4.09 | |||
| Variance | 16.77 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.52) | |||
| Total Risk Alpha | (0.87) | |||
| Treynor Ratio | (0.09) | |||
| Maximum Drawdown | 34.0 | |||
| Value At Risk | (4.33) | |||
| Potential Upside | 4.02 | |||
| Skewness | (3.51) | |||
| Kurtosis | 22.38 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.08) | |||
| Mean Deviation | 2.32 | |||
| Coefficient Of Variation | (1,854) | |||
| Standard Deviation | 4.09 | |||
| Variance | 16.77 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.52) | |||
| Total Risk Alpha | (0.87) | |||
| Treynor Ratio | (0.09) | |||
| Maximum Drawdown | 34.0 | |||
| Value At Risk | (4.33) | |||
| Potential Upside | 4.02 | |||
| Skewness | (3.51) | |||
| Kurtosis | 22.38 |
Consider Syndax Pharmaceuticals' intraday indicators
Syndax Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Syndax Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Syndax Pharmaceuticals Corporate Filings
8K | 18th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 17th of June 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 16th of May 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Syndax Stock media impact
Far too much social signal, news, headlines, and media speculation about Syndax Pharmaceuticals that are available to investors today. That information is available publicly through Syndax media outlets and privately through word of mouth or via Syndax internal channels. However, regardless of the origin, that massive amount of Syndax data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Syndax Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Syndax Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Syndax Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Syndax Pharmaceuticals alpha.
Syndax Pharmaceuticals Corporate Management
| Briggs MD | Head Pres | Profile | |
| Steven Closter | Chief Officer | Profile | |
| Michael MBA | CEO Director | Profile | |
| Steve Sabus | Chief Officer | Profile | |
| Joseph MD | Member Officer | Profile | |
| Ronald Evans | Advisor CoFounder | Profile | |
| Sharon Klahre | Vice Communications | Profile |
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.